0

“Behind the Buzz” Show: Featuring Spinalcyte, LLC CEO Pete O’Heeron

Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal replacement using human dermal fibroblasts. Currently, SpinalCyte holds 39 U.S. and international issued patents and has filed for an additional 100+ patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure […]

0

“Behind the Buzz” Show: Featuring Children’s Tumor Foundation President Annette Bakker

The Children’s Tumor Foundation (CTF) is a foundation dedicated to improving the health and well-being of individuals and families affected by neurofibromatosis (NF). The Foundation is the largest private funder of NF research and works to create the best forms of treatment for sufferers of NF. Annette Bakker, the Children’s Tumor Foundation’s President and Chief […]

0

Behind the Buzz Show: INmune Bio Inc. (NASDAQ: INMB) Corporate Overview

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many […]

0

“Buzz on the Street” Show: Pressure Biosciences (OTCQB: PBIO) Presents at Gynecologic Cancer Meeting

Pressure BioSciences, Inc. (OTCQB: PBIO) announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of a new, innovative workflow for the analysis of proteins from cancer biopsy samples. This workflow was presented in a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September […]

0

“Buzz on the Street” Show: Q BioMed Inc. (OTCQB: QBIO) Partnership with Jubilant Radiopharma

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it has entered into an exclusive distribution agreement for its non-opioid metastatic cancer pallion drug, Strontium-89 Chloride Injection USP (Strontium-89)/Metastron™, with Jubilant Radiopharma for the United States market. Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, […]